NASDAQ:OBSV ObsEva (OBSV) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitors About ObsEva Stock (NASDAQ:OBSV) Get ObsEva alerts:Sign Up Key Stats Today's Range N/A50-Day Range N/A52-Week Range N/AVolumeN/AAverage Volume8.94 million shsMarket Capitalization$7.94 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview ObsEva SA was a biopharmaceutical company focused on developing and commercializing therapies for women’s health. Founded in Geneva, Switzerland, the company concentrated on reproductive-health conditions, including uterine fibroids, endometriosis and infertility. Its principal product candidate was linzagolix, an oral gonadotropin-releasing hormone antagonist developed for the treatment of uterine fibroids and endometriosis-associated symptoms. Linzagolix received marketing authorization in the European Union under the brand name Yselty for the treatment of moderate-to-severe symptoms associated with uterine fibroids in adult women of reproductive age. ObsEva also evaluated other reproductive-health drug candidates during its development history, including treatments intended to support embryo implantation and fertility procedures. ObsEva operated internationally, with corporate roots in Switzerland and clinical-development and commercial activities directed toward markets in Europe and the United States. The company later encountered significant financial difficulties and entered insolvency proceedings, and its Nasdaq listing was subsequently discontinued. Commercial rights to Yselty have been associated with Theramex in certain markets. ObsEva was historically led by executives including co-founder and Chief Executive Officer Ernest Loumaye.AI Generated. May Contain Errors. Read More Receive OBSV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ObsEva and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. OBSV Stock News HeadlinesObsEva SA OBSNNovember 11, 2023 | morningstar.comMObsEva SA OBSEFNovember 11, 2023 | morningstar.comMWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one that gets burned with every transaction on what analysts are calling America's new financial grid. The Nasdaq has received SEC approval to move stocks onto blockchain rails, and BlackRock CEO Larry Fink dedicated his entire 2026 annual letter to this infrastructure shift. Blockchain analyst Andy Howard is calling this asset 'Digital Oil' - and says institutional buyers are already positioned.October 14 at 1:00 AM | Awesomely (Ad)ObsEva (NASDAQ: OBSV)June 18, 2023 | fool.comObsEva Files Year End 2022 Financial StatementsMarch 31, 2023 | finance.yahoo.comObsEva Announces Progress Towards its Plans to Consolidate Operations in Switzerland: Delisting of OBSV from The Nasdaq Stock Market effective March 23, 2023March 15, 2023 | finance.yahoo.comObsEva Names Fabien De Ladonchamps CEO, Ernest Loumaye Interim ChairmanMarch 13, 2023 | markets.businessinsider.comObsEva Announces Update Towards its Strategic Reorganization to Consolidate Operations in SwitzerlandMarch 13, 2023 | finance.yahoo.comSee More Headlines OBSV Stock Analysis - Frequently Asked Questions How were ObsEva's earnings last quarter? ObsEva SA (NASDAQ:OBSV) issued its quarterly earnings results on Thursday, November, 4th. The company reported $0.01 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.22) by $0.23. When did ObsEva IPO? ObsEva (OBSV) raised $98 million in an initial public offering on Thursday, January 26th 2017. The company issued 6,500,000 shares at a price of $14.00-$16.00 per share. Credit Suisse, Jefferies and Leerink Partners served as the underwriters for the IPO. What other stocks do shareholders of ObsEva own? Based on aggregate information from My MarketBeat watchlists, some other companies that ObsEva investors own include NIO (NIO), Bionano Genomics (BNGO), SNDL (SNDL), Inovio Pharmaceuticals (INO), Plug Power (PLUG), Alibaba Group (BABA) and Sorrento Therapeutics (SRNE). Company Calendar Last Earnings11/04/2021Today10/14/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:OBSV CIK1685316 Webwww.obseva.com Phone(122) 552-3840FaxN/AEmployees50Year Founded2012Profitability EPS (Trailing Twelve Months)($0.92) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$58.38 million Net MarginsN/A Pretax MarginN/A Return on Equity-416.36% Return on Assets-92.01% Debt Debt-to-Equity RatioN/A Current Ratio0.61 Quick Ratio0.61 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.41 per share Price / BookN/AMiscellaneous Outstanding Shares77,971,000Free Float66,743,000Market Cap$7.94 million OptionableNot Optionable Beta0.68 Social Links 10 Best Stocks to Own in Fall 2026AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.Get This Free Report This page (NASDAQ:OBSV) was last updated on 10/13/2026 by MarketBeat.com Staff. From Our PartnersMicroscopic footage reveals immune cells destroying cancer cellsTime-lapse footage from a recent clinical study shows Natural Killer cells attacking and eliminating cancer ce...Market Tactic | SponsoredA new income category is drawing serious money - here's whyForbes recently called a new category of exchange-traded income funds a 'golden era,' and Bloomberg noted the ...Investors Alley | SponsoredElon pays this company. Every time.Every Tesla built since 2012 pays this small, overlooked supplier a fee for its technology. So does every Star...Behind the Markets | SponsoredElon will prove them wrong againElon Musk's critics said self-driving cars were a pipe dream. Today, Tesla robotaxis carry passengers with no ...Paradigm Press | SponsoredA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | SponsoredWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | SponsoredDid you grab your copy yet?Bill Poulos's Top 10 Stocks to Buy This Quarter report is still available free, but not for long. Every quarte...Profits Run | SponsoredElon Musk’s One Stock Retirement PlanJeff Brown picked Nvidia in 2016, before it surged 37,000 percent. Now he's tracking a small AI company he say...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ObsEva SA Please log in to your account or sign up in order to add this asset to your watchlist. Share ObsEva With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
